| Document |
Document Title |
|
WO/2016/115455A2 |
Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, w...
|
|
WO/2016/110499A1 |
This disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof: in which m, p, A, Ar1, Ar2, Ar3, R1, R2, and R3 are defined in the specification. The compounds of formula (I) can be used as CGRP antagon...
|
|
WO/2016/106029A1 |
The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
|
|
WO/2016/103166A1 |
Co-crystals of Formula I compounds and their pharmaceutical compositions are novel therapeutics for the treatment of diseases, such as human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) infection, hepatitis C virus (HC...
|
|
WO/2016/102253A1 |
The present invention relates to herbicidally active thiazolopyridinones, in particular benzyloxy-substituted-phenyl-thiazolopyridinone derivatives,of formula (I), wherein R1, R2, G, X, Y, Z and n are as defined herein. The invention fur...
|
|
WO/2016/104317A1 |
The present invention addresses the problems of providing a polymerizable compound which, when added to a polymerizable composition, has high storage stability without causing any crystal precipitation, etc. and of providing a polymeriza...
|
|
WO/2016/098793A1 |
A compound represented by general formula (I) (wherein Z represents -CR1R2-; R1 and R2 independently represent a hydrogen atom, a halogen atom, a hydroxy group or the like, or independently form, together with an atom adjacent thereto, a...
|
|
WO/2016/096967A1 |
The present invention provides compounds of formula (I) wherein X is O, S or NR10,wherein R10 is H, C1-30-alkyl, substituted C1-30-alkyl, C2-30-alkenyl, substituted C2-30-alkenyl, C2-30-alkynyl, substituted C2-30-alkynyl or C(0)-OR11, R1...
|
|
WO/2016/094509A1 |
The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and var...
|
|
WO/2016/091698A1 |
The present invention relates to compounds of formula (I), wherein R1, R2and R3are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds ...
|
|
WO/2016/094517A1 |
Small molecule Bcl-xL inhibitorsand Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-ap...
|
|
WO/2016/087418A1 |
The invention relates to novel bicyclic compounds, to agents containing said compounds, to the use thereof for controlling animal pests and to methods and intermediate products for the production thereof.
|
|
WO/2016/087417A1 |
The invention relates to novel bicyclic compounds, to agents containing said compounds, to the use thereof for controlling animal pests and to methods and intermediate products for the production thereof.
|
|
WO/2016/087373A1 |
The invention relates to novel bicyclic compounds, to the use thereof for controlling animal pests and to methods and intermediate products for the production thereof.
|
|
WO/2016/083490A1 |
This invention provides novel compounds of formulae (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein the substituents are as defined in the specification. The present invention also relates to the...
|
|
WO/2016/075296A1 |
The disclosure relates to certain novel substituted ring-fused thiazolino 2- pyridones of Formula I, to processes for preparing such compounds, to their use in treating a bacterial infection such as a Chlamydia infection, to methods for ...
|
|
WO/2016/071211A1 |
The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pr...
|
|
WO/2016/071499A1 |
The present invention relates to the use of substituted 3-pyridyl heterobicyclic compounds of formula I as agrochemical pesticides. Furthermore, the present invention relates to novel substituted 3-pyridylheterobicyclic compounds of form...
|
|
WO/2016/066142A1 |
Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
|
|
WO/2016/066241A1 |
The invention relates to a novel process for preparing 5H- [1,2,5]thiadiazolo[3,4-f]isoindole-5,7(6H)-dione ("TID") derivatives, especially for preparing 4,8-diaryl-TID derivatives, to novel intermediates obtained and/or used in this pro...
|
|
WO/2016/060173A1 |
The present invention provides a compound that has a maximum absorption in a wavelength range of 350-550 nm and functions as a dichroic pigment. Provided is a compound represented by formula (1): [In the formula, R1 represents a hydrogen...
|
|
WO/2016/060174A1 |
The present invention provides a compound that has a maximum absorption in a wavelength range of 350-550 nm and functions as a dichroic pigment. Provided is a compound represented by formula (1): [In the formula, R1 represents a hydrogen...
|
|
WO/2016/060172A1 |
The present invention provides a compound that has a maximum absorption in a wavelength range of 350-550 nm and functions as a dichroic pigment. Provided is a compound represented by formula (1): [In the formula, R1 represents a C1-20 al...
|
|
WO/2016/056606A1 |
Provided is a novel compound having anti-virus activity. The compound or a salt thereof, is characterized by being represented by formula (I). R1-R3 independently represent a H atom, halogen atom, C1-6 alkyl group, C1-6 alkoxy group, C2-...
|
|
WO/2016/055431A1 |
Substituted pyrimidinium compounds of the general formula (I), wherein X, Y, Z, R1, R2, A and Het are defined as in the description, are useful for controlling invertebrate pests.
|
|
WO/2016/055553A1 |
The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including ...
|
|
WO/2016/055496A1 |
The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres...
|
|
WO/2016/053828A1 |
In its many embodiments, the present invention provides certain C5-C6 fused tricyclic iminothiadiazine compounds, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said ta...
|
|
WO/2016/051265A1 |
The present invention relates to a preparation of a novel azo-dye (formula I) and Schiff base (formula II) compounds and its derivatives (formula III and IV). Further, the invention relates to a use of synthesized azo-dye and Schiff base...
|
|
WO/2016/054491A1 |
Compounds of formula I' and formula II' and their pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity for the treatment of diseases and conditions associated with kinase activity, including PI3 kinase...
|
|
WO/2016/045769A1 |
The invention relates to heterocyclic compounds with benzo[c]coumarin structures and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2016/042451A1 |
The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein f...
|
|
WO/2016/042172A1 |
A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for use in the treatment of cancer, an inflammatory disorder,an autoimmunity disorder or a neurodegenerative disorder.
|
|
WO/2016/043996A1 |
The present invention provides a compound of Formula I: which is crystalline. The compound of Formula (I) is useful in the treatment of Akzheimer's disease (BACE imnhibitor).
|
|
WO/2016/043997A1 |
The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula I, or a pharmaceutically accep...
|
|
WO/2016/043260A1 |
A compound represented by general formula (I) (wherein n represents an integer of 2 to 5; R1 represents a hydrogen atom, a halogen atom, a cyano group, a nitro group, a substituted or unsubstituted C1-6 alkyl group or the like; R3 repres...
|
|
WO/2016/044771A1 |
Compounds having a structure of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein A, L, X, R1 and R2, are as defined herein are provided. Pharmaceutical compositions comprising such co...
|
|
WO/2016/042452A1 |
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibiti...
|
|
WO/2016/034634A1 |
The present invention relates to a compound with the following formula: formula (I) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to ...
|
|
WO/2016/035814A1 |
The purpose of the present invention is to provide a compound having an exceptional JAK1 inhibitory effect. Examples of the present invention include pyrazolothiazole compounds represented by general formula [I], and pharmacologically ac...
|
|
WO/2016/030443A1 |
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
|
|
WO/2016/033486A1 |
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, (I) and ph...
|
|
WO/2016/028110A1 |
The present invention relates to a plurality of host materials and an organic electroluminescent device comprising the same. By comprising a specific combination of a plurality of host compounds, the organic electroluminescent device acc...
|
|
WO/2016/021706A1 |
A compound represented by formula (I) or a salt thereof that has a blood LDL cholesterol-lowering action and is useful as an active ingredient of a drug (R1 indicates a C1-6 alkyl group, halogen atom, or the like; A indicates a phenylene...
|
|
WO/2016/016472A1 |
A compound of formula (I') wherein R6 is H, C1-6alkyl, -(CH2)pCOOH, -(CH2)pCOOC1-6alkyl, - (CH2)pCONH2, -(CH2)pCONHC1-6alkyl, -(CH2)pCON(C1-6alkyl)2, R7 is as defined for R6; or and R7 taken together with the atoms joining them can form ...
|
|
WO/2016/017688A1 |
The problem of the present invention is to provide an organic electroluminescence element in which light emission efficiency can be improved. This organic electroluminescence element has at least one organic layer including a light-emitt...
|
|
WO/2016/012422A1 |
The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pre...
|
|
WO/2016/012536A1 |
The present invention relates to the use of a class of novel isothiazolo[4,3-b]pyridine derivatives as well as to pharmaceutical compositions comprising one or more of said isothiazolo[4,3- b]pyridine derivatives and one or more pharmace...
|
|
WO/2016/011930A1 |
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for e...
|
|
WO/2016/008433A1 |
Provided herein are novel substituted urea derivatives, and pharmaceutical compositions thereof. Also provided herein are uses of the compounds or pharmaceutical compositions thereof for preventing, managing, treating or lessening a prol...
|
